South Africa’s green hydrogen ambitions advanced this week after the Hive Hydrogen Coega project selected a major technology package for its planned large-scaleSouth Africa’s green hydrogen ambitions advanced this week after the Hive Hydrogen Coega project selected a major technology package for its planned large-scale

South Africa’s US$5.8bn Hydrogen Push Advances

2026/05/29 15:00
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

South Africa’s green hydrogen ambitions advanced this week after the Hive Hydrogen Coega project selected a major technology package for its planned large-scale green ammonia production facility, reinforcing the country’s growing role in the global energy transition economy.

The US$5.8 billion development, located within the Coega Special Economic Zone near the Port of Ngqura in South Africa’s Eastern Cape province, has progressed toward commercial readiness following the selection of Danish engineering group Topsoe to supply an integrated electrolyser and green ammonia solution.

The project is expected to produce approximately one million tonnes of green ammonia annually, targeting export markets across Europe and Asia as countries accelerate industrial decarbonisation strategies and seek long-term low-carbon fuel supply partnerships.

The advancement highlights how African economies with strong renewable energy resources are increasingly attempting to position themselves within emerging hydrogen and green fuel supply chains. Alongside South Africa, countries including Namibia, Egypt and Morocco have intensified efforts to attract large-scale investment into renewable-powered industrial export projects.

The Coega initiative is expected to rely primarily on solar and wind energy generation to power electrolysis systems that produce green hydrogen before conversion into ammonia for export and industrial use. Green ammonia is increasingly viewed as one of the most commercially viable methods of transporting hydrogen internationally due to existing storage and maritime infrastructure compatibility.

Beyond fertiliser markets, green ammonia is also attracting growing interest as a potential maritime fuel and as a decarbonisation solution for hard-to-abate sectors including heavy industry, chemicals and shipping.

The technology selection is considered strategically important because electrolysis efficiency remains one of the central economic variables in green hydrogen production. High electricity consumption continues to represent one of the largest cost challenges facing the sector globally.

The project also reflects broader competition emerging between regions seeking first-mover advantage within future hydrogen export markets. European and Asian economies are increasingly pursuing long-term supply diversification strategies as decarbonisation policies accelerate across industrial sectors.

For South Africa, the development could contribute toward industrial diversification, export growth and renewable infrastructure expansion within the Eastern Cape. It also reinforces the strategic importance of integrated port, industrial and energy infrastructure in supporting future energy-transition industries across Africa.

Despite growing investor interest, large-scale hydrogen projects across the continent still face substantial financing, infrastructure and execution challenges. Transmission capacity, water availability, long-term offtake agreements and capital intensity remain among the principal constraints slowing final investment decisions across many proposed projects.

Commercial operations for the Hive Hydrogen Coega project are currently expected toward the end of the decade, subject to financing completion, regulatory approvals and final investment decision milestones.

The post South Africa’s US$5.8bn Hydrogen Push Advances appeared first on FurtherAfrica.

Market Opportunity
HIVE Logo
HIVE Price(HIVE)
$0.06139
$0.06139$0.06139
-6.04%
USD
HIVE (HIVE) Live Price Chart

SPACEX(PRE) Launchpad

SPACEX(PRE) LaunchpadSPACEX(PRE) Launchpad

Register for a chance to win a free lucky draw

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Bitcoin shorts risk $2.5 billion liquidation at $72K: Are bears in danger?

Bitcoin shorts risk $2.5 billion liquidation at $72K: Are bears in danger?

Bitcoin is poised for a reversal if ETF demand returns or a ceasefire occurs, potentially crushing short sellers in a massive price squeeze.
Share
Coin Telegraph2026/04/04 19:58
Robotics Automation Prototyping: Engineering Kinetic Agility into End-Effectors

Robotics Automation Prototyping: Engineering Kinetic Agility into End-Effectors

Inertia is the invisible tax on modern industrial throughput. Every millisecond a robotic arm spends decelerating, or waiting for high-frequency vibrations to settle
Share
Techbullion2026/04/02 18:25

RealStocks Now Live

RealStocks Now LiveRealStocks Now Live

Trade real U.S. stock via regulated brokerage